Journal Entry #3XX
Date: Unknown Time of Day: Unknown
Experiment B14-D5T: Success Subject [REDACTED] Status: Alive
Experiment B14-D5T was designed to enhance a Hunter/Huntress' Aura and Semblance through intravenous injections. Through repeated exposure, Subject [REDACTED] has reacted positively to B14-D5T. [REDACTED] has given Subject [REDACTED] permission to self-administer B14-D5T.
First exposure began with 1mg B14-D5T, injected by [REDACTED]. Subject [REDACTED] was restrained on experiment table. Subject [REDACTED] appeared to have an extreme adverse reaction, with symptoms including (but not limited to) nausea, hallucinations, sweating and inability to control Semblance. Subject [REDACTED] flatlined and was resuscitated. Transferred to recovery station and monitored for seven days.
Second exposure began with 2mg B14-D5T, injected by [REDACTED]. Subject [REDACTED] was restrained on experiment table. Subject [REDACTED] appeared to have an extreme adverse reaction, with symptoms including (but not limited to) nausea, hallucinations, sweating and seizures. Subject [REDACTED] flatlined and was resuscitated. Transferred to recovery station and monitored for seven days.
Third exposure began with 5mg B14-D5T, injected by [REDACTED]. Subject [REDACTED] was restrained on experiment table. Subject [REDACTED] appeared to have an adverse reaction, with symptoms including (but not limited to) nausea, hallucinations, sweating, seizures and aggressive behavior. Transferred to recovery station and monitored for five days.
Fourth exposure began with 5mg B14-D5T, injected by [REDACTED]. Subject [REDACTED] was restrained on experiment table. Subject [REDACTED] appeared to have an adverse reaction, with symptoms including (but not limited to) sweating, seizures and aggressive behavior. Transferred to recovery station and monitored for three days.
Fifth exposure began with 10mg B14-D5T, injected by [REDACTED]. Subject [REDACTED] appeared to have an adverse reaction, with sweating and nausea. Transferred to recovery station and monitored for two days.
Sixth exposure began with 10mg B14-D5T, injected with supervision by Subject [REDACTED]. Subject [REDACTED] appeared to have an adverse reaction, with nausea and staining of skin at injection point. Transferred to recovery station and monitored for 24 hours.
Seventh exposure began with 15mg B14-D5T, injected with supervision by Subject [REDACTED]. Subject [REDACTED] appeared to have an adverse reaction, with nausea and staining of skin at injection point. Transferred to recovery station and monitored for 24 hours.
Eighth exposure began with 25mg B14-D5T, injected with supervision by Subject [REDACTED]. Subject [REDACTED] appeared to have no adverse reaction, with staining of skin and veins at injection point. Transferred to recovery station and monitored for 24 hours.
Ninth exposure began with 40mg B14-D5T, injected by Subject [REDACTED]. Subject [REDACTED] appeared to have no adverse reaction, with staining of skin and veins at injection point and lower left forearm. Transferred to recovery station and monitored for 24 hours. Tenth exposure began with 2g B14-D5T, injected by Subject [REDACTED]. Subject [REDACTED] appeared to have an adverse reaction, with symptoms including (but not limited to) nausea, sweating, seizures and hallucinations. Subject [REDACTED] flatlined and resuscitated. Transferred to recovery station and monitored for three days.
Eleventh exposure began with 25mg B14-D5T, injected with supervision by Subject [REDACTED]. Subject [REDACTED] appeared to have no adverse reaction, with staining of skin and veins at injection point and lower left forearm. Transferred to recovery station and monitored for 24 hours.
Twelfth exposure began with 40mg B14-D5T, injected with supervision by Subject [REDACTED]. Subject [REDACTED] appeared to have no adverse reaction; staining of skin, veins and fingers at injection point and lower left forearm and hand. Transferred to recovery station and monitored for 24 hours.